Yasuji Miyakita

Dr. Yasuji Miyakita

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2012 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
SSSoichiro Shibui
Soichiro Shibui
YNYOSHITAKA NARITA
YOSHITAKA NARITA
JMJunki Mizusawa
Junki Mizusawa
TBTakaaki Beppu
Takaaki Beppu
KOKuniaki Ogasawara
Kuniaki Ogasawara
KNKazuhiro Nomura
Kazuhiro Nomura

18 August 2024 in Cancers
Verified
Journal Article
Open access
PDF file
TTTakahiro Tsuchiya
Takahiro Tsuchiya
DKDaisuke Kawauchi
Daisuke Kawauchi
MOMakoto Ohno
Makoto Ohno
YMYasuji Miyakita
Yasuji Miyakita
Masamichi TakahashiMasamichi Takahashi
Masamichi Takahashi
YNYOSHITAKA NARITA
YOSHITAKA NARITA
Isocitrate dehydrogenase (IDH) wild-type glioblastoma (GBM) is a highly aggressive brain tumor with a high recurrence rate despite adjuvant treatment. This study aimed to evaluate the risk factors for non-local recurrence of GBM. In the present study, we analyzed 104 GBMs with a single lesion (non-multifocal or multicentric). Univariate analysis revealed that subventricular zone (SVZ) involvement was significantly associated with non-local recurrence (hazard ratio [HR]: 2.09 [1.08–4.05]). Tumors in contact with the trigone of the lateral ventricle tended to develop subependymal dissemination (p = 0.008). Ventricular opening via surgery did not increase the risk of non-local recurrence in patients with SVZ involvement (p = 0.190). A systematic review was performed to investigate the risk of non-local recurrence, and 21 studies were identified. A meta-analysis of previous studies confirmed SVZ involvement (odds ratio [OR]: 1.30 [1.01–1.67]) and O-6-methylguanine DNA methyltransferase promoter methylation (OR: 1.55 [1.09–2.20]) as significant risk factors for local recurrence. A time-dependent meta-analysis revealed a significant association between SVZ involvement and dissemination (HR: 1.69 [1.09–2.63]), while no significant association was found for distant recurrence (HR: 1.29 [0.74–2.27]). Understanding SVZ involvement and specific tumor locations associated with non-local recurrence provides critical insights for the management of GBM.

7 July 2020 in Biomedicine Hub
Verified
Journal Article
Open access
PDF file
KKKenya Kobayashi
Kenya Kobayashi
FMFUMIHIKO Matsumoto
FUMIHIKO Matsumoto
YMYasuji Miyakita
Yasuji Miyakita
MAMasaki Arikawa
Masaki Arikawa
GOGo Omura
Go Omura
SYSeiichi Yoshimoto
Seiichi Yoshimoto
Background: To determine factors that delay surgical recovery and increase intraoperative hemorrhage in skull base surgery. Methods: Factors related to delayed postoperative recovery were retrospectively reviewed in 33 patients who underwent open skull base surgery. Early and late recovery phases were assessed as “days required to walk around the ward (DWW)” and “length of hospital stay (LHS),” respectively. Intraoperative blood loss was cal­culated every hour and analyzed in 4 steps, i.e., craniotomy and intracranial manipulation, cranial fossa osteotomy, extracranial osteotomy, and reconstruction. Results: More than 4,000 mL of blood loss (B = 2.7392, Exp[B] = 15.4744; 95% CI 1.1828–202.4417) and comorbidi­ty (B = 2.3978, Exp[B]) = 10.9987; 95% CI 1.3534–98.3810) significantly prolonged the DWW; the occurrence of postoperative complications significantly delayed the LHS (p = 0.0316). Tumor invasion to the hard palate, the maxillary sinus, the pterygopalatine fossa, the base of the pterygoid process, the sphenoid sinus, the middle cranial fossa, and the cavernous sinus and a long operation time (>13 h) were associated with increased total hemorrhage. The optimal cut-off hemorrhage volume associated with total massive blood loss in craniotomy and intracranial manipulation (AUC = 0.8364), cranial fossa osteotomy (AUC = 0.8000), and extracranial osteotomy (AUC = 0.8545) was 1,111, 750, and 913 mL, respectively. Persistent infection (6%) and neuropsychiatric disorder (6%) are direct causes of delayed LHS. Conclusion: Blood loss, comorbidity, and postoperative complications were risk factors for delayed surgical recovery. Meticulous preoperative planning, intraoperative surefire hemostasis, and perioperative holistic management are prerequisites for safe skull base surgery.

24 July 2024 in Cancers
Verified
Journal Article
Open access
PDF file
SOSho Osawa
Sho Osawa
YMYasuji Miyakita
Yasuji Miyakita
Masamichi TakahashiMasamichi Takahashi
Masamichi Takahashi
MOMakoto Ohno
Makoto Ohno
SYShunsuke Yanagisawa
Shunsuke Yanagisawa
YNYOSHITAKA NARITA
YOSHITAKA NARITA
Awake surgery contributes to the maximal safe removal of gliomas by localizing brain function. However, the efficacy and safety thereof as a treatment modality for glioblastomas (GBMs) have not yet been established. In this study, we analyzed the outcomes of awake surgery as a treatment modality for GBMs, response to awake mapping, and the factors correlated with mapping failure. Patients with GBMs who had undergone awake surgery at our hospital between March 2010 and February 2023 were included in this study. Those with recurrence were excluded from this study. The clinical characteristics, response to awake mapping, extent of resection (EOR), postoperative complications, progression-free survival (PFS), overall survival (OS), and factors correlated with mapping failure were retrospectively analyzed. Of the 32 participants included in this study, the median age was 57 years old; 17 (53%) were male. Awake mapping was successfully completed in 28 participants (88%). A positive response to mapping and limited resection were observed in 17 (53%) and 13 participants (41%), respectively. The EOR included gross total, subtotal, and partial resections and biopsies in 19 (59%), 8 (25%), 3 (9%), and 2 cases (6%), respectively. Eight (25%) and three participants (9%) presented with neurological deterioration in the acute postoperative period and at 3 months postoperatively, respectively. The median PFS and OS were 15.7 and 36.9 months, respectively. The time from anesthetic induction to extubation was statistically significantly longer in the mapping failure cohort than that in the mapping success cohort. Functional areas could be detected during awake surgery in participants with GBMs. Thus, awake mapping influences intraoperative discernment, contributes to the preservation of brain function, and improves treatment outcomes.

3 April 2025 in Neurosurgery Practice
Verified
Journal Article
Open access
SOSho Osawa
Sho Osawa
MOMakoto Ohno
Makoto Ohno
YMYasuji Miyakita
Yasuji Miyakita
Masamichi TakahashiMasamichi Takahashi
Masamichi Takahashi
SYShunsuke Yanagisawa
Shunsuke Yanagisawa
YNYOSHITAKA NARITA
YOSHITAKA NARITA
BACKGROUND AND OBJECTIVES: Frameless neuronavigation–guided stereotactic biopsy (SB) is a common surgical technique for diagnosing intracranial lesions. A frameless SB is generally performed under general anesthesia; however, no reports are available on the efficacy and safety of frameless SBs under local anesthesia (LA). This study reports the surgical outcomes, diagnostic yield, and feasibility of molecular analyses after performing a frameless SB under LA (SB-LA). METHODS: The study retrospectively included patients who underwent a frameless SB-LA at our institute between March 2015 and January 2024. The clinical characteristics, intraoperative findings, completion rate of surgical procedure, complications, diagnostic yield, and feasibility of molecular analysis were analyzed retrospectively. RESULTS: The study included 80 patients. Surgical procedures were completed in 79 patients (98.7%); the diagnosis was confirmed in 76 cases (95.0%). The diagnoses included diffuse gliomas (n = 38, 47.5%), primary central nervous system lymphomas (PCNSL; n = 27, 33.8%), other brain tumors (n = 4, 5.0%), demyelinating diseases (n = 2, 2.5%), and normal brain/gliosis (n = 5, 6.3%). All samples were sufficient for basic molecular analyses of isocitrate dehydrogenase 1/2, telomerase reverse transcriptase promoter, H3 histone family 3A, serine/threonine kinase B-RAF, and O-6-methylguanine deoxyribonucleic acid methyltransferase promoter methylation in gliomas and myeloid differentiation primary response gene 88 for PCNSLs. A comprehensive genomic profiling test using next-generation sequencing was attempted in 9 cases and was feasible in 8. Asymptomatic hemorrhages occurred in 14 patients (17.5%); no symptomatic hemorrhage occurred. Neurological deficits were observed in 1 patient (1.3%) who developed symptomatic small cerebral infarction. The median period from the first visit to our hospital to surgery was 3 days (range 0-12) for PCNSL and 6.5 days (range 0-21) for primary glioblastoma, isocitrate dehydrogenase wild-type. CONCLUSION: Frameless SB-LAs can be performed safely with a high diagnostic yield and feasibility for molecular analysis. Frameless SB-LAs improve early diagnoses and therapeutic interventions without compromising molecular information.

20 May 2009 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
HMH. Momota
H. Momota
YNYukiya Narita
Yukiya Narita
YMYasuji Miyakita
Yasuji Miyakita
ASA. Shinomiya
A. Shinomiya
AMA. Maeshima
A. Maeshima
SSS. Shibui
S. Shibui
E13028 Background: BCL-6 expression has been reported to be associated with a better prognosis in PCNSL. However, significant differences of B-cell lymphoma subtypes exist in different geographic regions. The objectives of this study were to characterize the immunophenotypes of PCNSL in Japan and to determine their utility in predicting clinical outcomes. Methods: Immunostaining for CD5, CD10, BCL-6, and MUM-1 was done to determine the profile of diffuse large B-cell lymphoma of PCNSL from 27 immunocompetent patients in Japan. Then, the authors evaluated whether clinical and immunophenotypic markers were associated with progression-free or overall survival. Results: Germinal center B-cell (GCB) marker CD10 was positive in 22% of PCNSL samples, while another GCB marker BCL-6 was positive in 48% of samples. Post-GCB marker MUM-1 was positive in 81% of samples. Poor prognostic marker of systemic B-cell lymphoma CD5 was expressed in 15% of samples. In univariate analyses, only BCL-6 expression had a significant effect on progression-free survival (median, 6.1 months in BCL-6-positive patients versus 15.6 months in BCL-6-negative patients; p = 0.037). Patients with BCL-6 expression had a trend towards longer overall survival but nonsignificant. GCB subgroup (CD10-positive or CD10-negative/BCL-6-positive/MUM-1-negative) was not significantly associated with favorable survival. Conclusions: BCL-6 expression is associated with a poor prognosis in patients with PCNSL. The discrepancy between the reports from other groups and our results is potentially due to the racial, geographic or immunophenotypic differences of PCNSL. No significant financial relationships to disclose.